1 Min Read
Dec 2 (Reuters) - Basilea Pharmaceutica AG :
* Expands oncology drug candidate BAl101553 clinical phase 1/2a oral study to include glioblastoma patients Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.